
FDA panel discussing Moderna COVID-19 boosters
A recommendation is expected on whether the shot should be authorized.
A Food and Drug Administration (FDA) advisory committee will decide today whether the agency should recommend booster shots of the Moderna COVID-19 vaccine.
As part of a two-day meeting, the FDA Vaccines and Related Biological Products Advisory Committee will discuss whether to recommend the third half-dose of the vaccine at least six months after completion of the initial regimen.
The documents also show that the booster shots appear safe, with the reactogenicity and adverse event profile similar to that seen after the second dose of the vaccine.
Moderna is seeking an expansion of the drug’s emergency use authorization similar to that given to the Pfizer COVID-19 vaccine, Comirnaty.
The World Health Organization has called for a
“To make that happen, we need everyone’s cooperation, especially the handful of countries and companies that control the global supply of vaccines,” WHO Director General Tedros Adhanom Ghebreyesus said in an Aug. 4 briefing.
Newsletter
Stay informed and empowered with Medical Economics enewsletter, delivering expert insights, financial strategies, practice management tips and technology trends — tailored for today’s physicians.